Yam gruel shows promise for heart health after stent surgery
NCT ID NCT07589036
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether eating yam gruel daily for 12 weeks could improve cholesterol levels in 72 people who had a heart stent placed. Participants either received standard care alone or standard care plus yam gruel as a partial dinner replacement. Researchers measured cholesterol and body mass index at the start, 8 weeks, and 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Dioscorea yam gruel (dietary supplement)
- What this could lead to
- If it works, this could point toward a simple dietary addition to help manage cholesterol after heart procedures.
- What could go wrong
- This is a small, completed trial with only 72 participants. The effect may be modest and not apply to everyone. Diet changes alone are unlikely to replace standard medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
72 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Meeting the diagnostic criteria for coronary heart disease (2020 edition) * Undergoing percutaneous coronary intervention (PCI) * Aged between 18 and 75 years * Having been on a stable dose of statin therapy for at least 4 weeks prior to screening * Being in a stable clinical condition, conscious, providing informed consent, and participating voluntarily Exclusion Criteria: * Low-density lipoprotein cholesterol (LDL-C) level \< 70 mg/dL(\<1.81mmol/L) at screening * Complicating with other severe diseases or diseases that affect blood lipid levels, such as malignant tumors, acute cerebrovascular disease, nephrotic syndrome, severe liver disease, Cushing's syndrome, and others * Pregnancy or lactation * Concurrently participating in other dietary or exercise intervention programs
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Coronary heart disease (CHD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
900th Hospital of PLA Joint Logistic Support Force
Fuzhou, Fujian, 350025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A balloon that coats heart arteries in drug, no stent left behind
- Can a traditional chinese medicine injection ease heart failure symptoms?
- Can an AI trained on real heart patients outsmart generic chatbots?
- Can balloon timing make or break heart artery success?
- Can your smartwatch replace a medical heart test? scientists put apple watch to the test
- Sound waves vs X-Rays: which guides heart stents better?